이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bayer 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bill Anderson

최고 경영자

€11.8m

총 보상

CEO 급여 비율	14.3%
CEO 임기	1.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	7.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bill Anderson 의 보수는 Bayer 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

보상 대 시장: Bill 의 총 보상 ($USD 12.68M )은 BG 시장( $USD 4.48M ).

보상과 수익: Bill 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Bill Anderson (58 yo)

1.2yrs

테뉴어

€11,804,104

보상

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Anderson	Chairman of the Management Board & CEO	1.2yrs	€11.80m	데이터 없음
Wolfgang Nickl	CFO & Member of Management Board	6.2yrs	€3.42m	데이터 없음
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	5.6yrs	€3.43m	데이터 없음
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.4yrs	€3.65m	데이터 없음
Heike Prinz	Chief Talent Officer	less than a year	€2.53m	데이터 없음
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	데이터 없음	데이터 없음
Sebastian Guth	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Jost Reinhard	Head of Investor Relations	less than a year	데이터 없음	데이터 없음
Michael Preuss	Head of Communications	8.1yrs	데이터 없음	데이터 없음
Bernd-Peter Bier	Head of Group Finance	no data	데이터 없음	데이터 없음
Robert LaCaze	Executive VP & Head of the Oncology Strategic Business Unit	7.3yrs	데이터 없음	데이터 없음
Daniella Foster	SVP and Global Head of Public Affairs	4.8yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: BAYN 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul M. Achleitner	Member of Supervisory Board	22.2yrs	€225.00k	데이터 없음
Ertharin Cousin	Independent Member of the Supervisory Board	4.7yrs	€270.00k	데이터 없음
Heinz Webers	Employee Representative Member of Supervisory Board	2.2yrs	€205.00k	데이터 없음
Simone Bagel-Trah	Independent Member of Supervisory Board	10.2yrs	€227.00k	데이터 없음
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	데이터 없음	데이터 없음
Horst Baier	Independent Member of Supervisory Board	4.2yrs	€333.00k	데이터 없음
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.2yrs	€346.00k	데이터 없음
André van Broich	Member of Supervisory Board	12.2yrs	€271.00k	데이터 없음
Frank Löllgen	Member of Supervisory Board	8.6yrs	€268.00k	데이터 없음
Otmar Wiestler	Independent Member of Supervisory Board	9.7yrs	€237.00k	데이터 없음
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.1yrs	€509.00k	데이터 없음
Gunter Hilken	Chairman of Executive Board - Currenta	no data	데이터 없음	데이터 없음

7.9yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: BAYN 의 이사회는 경험(평균 재직 기간 7.9 년)으로 간주됩니다.

Bayer 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Bayer AG Announces CEO Changes

Recent updates

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.65 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New major risk - Dividend sustainability

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings released: EPS: €2.22 (vs €3.35 in 1Q 2022)

Upcoming dividend of €2.40 per share at 4.0% yield

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Bayer Aktiengesellschaft (XTRA:BAYN) acquired Targenomix GmbH.

Bayer Aktiengesellschaft Extends Development Program for Investigational Product Elinzanetant with Phase III Study in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week

Cinven Limited completed the acquisition of Environmental Science Professional business from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data from Innovative Science At ESMO Congress 2022

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Bayer Launches ForGround

U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Second quarter 2022 earnings released: €0.30 loss per share (vs €2.38 loss in 2Q 2021)

Bayer Aktiengesellschaft (XTRA:BAYN) signed a shareholders agreement to acquire 65% stake in CoverCress Inc. from Bunge Ventures and Chevron U.S.A. Inc.

Keensight Capital alongside management of Axxam entered into an agreement to acquire Axxam SpA from Bayer Aktiengesellschaft (XTRA:BAYN) and Zambon Company S.p.A.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령